Orchestra BioMed Holdings Statistics
Total Valuation
OBIO has a market cap or net worth of $143.51 million. The enterprise value is $125.94 million.
Important Dates
The last earnings date was Tuesday, August 12, 2025, after market close.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
OBIO has 53.95 million shares outstanding. The number of shares has increased by 7.26% in one year.
| Current Share Class | 53.95M |
| Shares Outstanding | 53.95M |
| Shares Change (YoY) | +7.26% |
| Shares Change (QoQ) | +0.41% |
| Owned by Insiders (%) | 2.80% |
| Owned by Institutions (%) | 14.01% |
| Float | 32.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 34.41 |
| Forward PS | 61.56 |
| PB Ratio | 486.49 |
| P/TBV Ratio | 486.49 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 42.78 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.10, with a Debt / Equity ratio of 55.44.
| Current Ratio | 2.10 |
| Quick Ratio | 1.99 |
| Debt / Equity | 55.44 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -34.18 |
Financial Efficiency
Return on equity (ROE) is -313.82% and return on invested capital (ROIC) is -143.16%.
| Return on Equity (ROE) | -313.82% |
| Return on Assets (ROA) | -77.32% |
| Return on Invested Capital (ROIC) | -143.16% |
| Return on Capital Employed (ROCE) | -276.61% |
| Revenue Per Employee | $42,057 |
| Profits Per Employee | -$995,700 |
| Employee Count | 70 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 1.69 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -56.46% in the last 52 weeks. The beta is 0.61, so OBIO's price volatility has been lower than the market average.
| Beta (5Y) | 0.61 |
| 52-Week Price Change | -56.46% |
| 50-Day Moving Average | 3.01 |
| 200-Day Moving Average | 4.13 |
| Relative Strength Index (RSI) | 43.14 |
| Average Volume (20 Days) | 387,079 |
Short Selling Information
The latest short interest is 506,574, so 0.94% of the outstanding shares have been sold short.
| Short Interest | 506,574 |
| Short Previous Month | 558,823 |
| Short % of Shares Out | 0.94% |
| Short % of Float | 1.58% |
| Short Ratio (days to cover) | 3.15 |
Income Statement
In the last 12 months, OBIO had revenue of $2.94 million and -$69.70 million in losses. Loss per share was -$1.83.
| Revenue | 2.94M |
| Gross Profit | 2.73M |
| Operating Income | -71.27M |
| Pretax Income | -51.64M |
| Net Income | -69.70M |
| EBITDA | -70.94M |
| EBIT | -71.27M |
| Loss Per Share | -$1.83 |
Full Income StatementBalance Sheet
The company has $33.92 million in cash and $16.35 million in debt, giving a net cash position of $17.57 million or $0.33 per share.
| Cash & Cash Equivalents | 33.92M |
| Total Debt | 16.35M |
| Net Cash | 17.57M |
| Net Cash Per Share | $0.33 |
| Equity (Book Value) | 295,000 |
| Book Value Per Share | 0.01 |
| Working Capital | 18.82M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$59.38 million and capital expenditures -$320,000, giving a free cash flow of -$59.70 million.
| Operating Cash Flow | -59.38M |
| Capital Expenditures | -320,000 |
| Free Cash Flow | -59.70M |
| FCF Per Share | -$1.11 |
Full Cash Flow StatementMargins
| Gross Margin | 92.66% |
| Operating Margin | -2,420.75% |
| Pretax Margin | -2,367.49% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.26% |
| Shareholder Yield | n/a |
| Earnings Yield | -48.57% |
| FCF Yield | -41.60% |
Analyst Forecast
The average price target for OBIO is $14.00, which is 426.32% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $14.00 |
| Price Target Difference | 426.32% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 85.13% |
| EPS Growth Forecast (5Y) | -21.00% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |